Assessment of K-ras mutation: a step toward personalized medicine for patients with colorectal cancer (Q37519514)

20 August 2017

1 reference

title

Assessment of K-ras mutation: a step toward personalized medicine for patients with colorectal cancer (English)

1 reference

20 August 2017

0 references

1 reference

personalized medicine

1 reference

5

Jaffer A Ajani

1 reference

Kevin F Staveley-O'Carroll

20 August 2017

series ordinal

3

object named as

Kevin F Staveley-O'Carroll

1 reference

20 August 2017

Yixing Jiang

1

1 reference

20 August 2017

Eric T Kimchi

series ordinal

2

1 reference

20 August 2017

Hua Cheng

series ordinal

4

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 August 2009

1 reference

20 August 2017

1 reference

20 August 2017

115

1 reference

20 August 2017

16

1 reference

20 August 2017

3609-3617

1 reference

Genetic alterations during colorectal-tumor development

20 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24434

The multidisciplinary management of gastrointestinal cancer. The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24434

21 January 2018

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24434

7 January 2021

New tumor-node-metastasis staging strategy for node-positive (stage III) rectal cancer: an analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24434

7 January 2021

Systemic therapy for colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24434

7 January 2021

Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24434

7 January 2021

ras mediates nerve growth factor receptor modulation of three signal-transducing protein kinases: MAP kinase, Raf-1, and RSK

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24434

7 January 2021

Phosphatidylinositol-3-OH kinase as a direct target of Ras

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24434

7 January 2021

Activated Ras interacts with the Ral guanine nucleotide dissociation stimulator

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24434

7 January 2021

Identification of the guanine nucleotide dissociation stimulator for Ral as a putative effector molecule of R-ras, H-ras, K-ras, and Rap

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24434

7 January 2021

PKB/Akt: connecting phosphoinositide 3-kinase to cell survival and beyond

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24434

7 January 2021

Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24434

7 January 2021

Ras oncogenes: split personalities

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24434

7 January 2021

Proteins regulating Ras and its relatives

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24434

7 January 2021

Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24434

7 January 2021

Prevalence of ras gene mutations in human colorectal cancers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24434

7 January 2021

Detection of high incidence of K-ras oncogenes during human colon tumorigenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24434

7 January 2021

A genetic model for colorectal tumorigenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24434

7 January 2021

Mutations in APC, Kirsten-ras, and p53--alternative genetic pathways to colorectal cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24434

7 January 2021

Near-diploid and near-triploid human sporadic colorectal adenocarcinomas differ for KRAS2 and TP53 mutational status

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24434

7 January 2021

Chromosomal instability and APC gene mutations in human sporadic colorectal adenomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24434

7 January 2021

Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24434

7 January 2021

K-ras and p53 mutations in aberrant crypt foci and colonic tumors from colon cancer patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24434

7 January 2021

Oncogenic K-ras promotes early carcinogenesis in the mouse proximal colon

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24434

7 January 2021

Clinical and pathological associations with allelic loss in colorectal carcinoma [corrected].

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24434

7 January 2021

Allelotype of colorectal carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24434

7 January 2021

Targeting RAS signalling pathways in cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24434

7 January 2021

Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24434

7 January 2021

Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24434

7 January 2021

Expression of matrix metalloproteinase matrilysin (MMP-7) was induced by activated Ki-ras via AP-1 activation in SW1417 colon cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24434

7 January 2021

Targeted disruption of the K-ras oncogene in an invasive colon cancer cell line down-regulates urokinase receptor expression and plasminogen-dependent proteolysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24434

7 January 2021

Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24434

7 January 2021

Oncogenic K-RAS is required to maintain changes in cytoskeletal organization, adhesion, and motility in colon cancer cells.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24434

7 January 2021

Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24434

7 January 2021

Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K-ras-2 mutation type

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24434

7 January 2021

K-ras and p16 aberrations confer poor prognosis in human colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24434

7 January 2021

K-ras mutations in patients with early colorectal cancers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24434

7 January 2021

Prognostic value of K-ras mutations and allelic imbalance on chromosome 18q in patients with resected colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24434

7 January 2021

The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24434

7 January 2021

Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24434

7 January 2021

EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24434

7 January 2021

Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24434

7 January 2021

The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24434

7 January 2021

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24434

7 January 2021

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24434

7 January 2021

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24434

7 January 2021

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24434

7 January 2021

Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24434

7 January 2021

Mutations of the BRAF gene in human cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24434

7 January 2021

Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24434

7 January 2021

Identifiers

DOI

10.1002/CNCR.24434

1 reference

20 August 2017

1 reference